^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Noxafil (posaconazole)

    i
    Other names: MK-5592, SCH 56592
    Associations

    News

    Trials
    Company:
    Ligand, Merck (MSD)
    Drug class:
    Cytochrome P450 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3d
    A Retrospective Study on the Correlation between Posaconazole Concentration and the Incidence of Clinical Adverse Reactions (ChiCTR2500114180)
    P=N/A, N=200, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    |
    Noxafil (posaconazole)
    3d
    A multicenter, randomized controlled phase II clinical study of oral posaconazole combined with chemotherapy and PD-1 inhibitors as neoadjuvant treatment for early or locally advanced triple-negative breast cancer (ChiCTR2500098742)
    P=N/A, N=40, Recruiting, Cancer Hospital of Shandong First Medical University (Shandong Cancer institute, Shandong Cancer Hospital); Cancer Hospital of Shandong First Medical | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Noxafil (posaconazole)
    5d
    MOMENTUM: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (clinicaltrials.gov)
    P1/2, N=84, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    Noxafil (posaconazole)
    11d
    Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (clinicaltrials.gov)
    P2, N=10, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Noxafil (posaconazole)
    16d
    A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers. (PubMed, Clin Pharmacol Drug Dev)
    Co-administration with posaconazole increased SGR-1505 exposure 3-fold...Asymptomatic, reversible indirect hyperbilirubinemia occurred, consistent with inhibition of UGT1A1. SGR-1505 was well-tolerated and exhibited favorable pharmacokinetic and pharmacodynamic properties, supporting further clinical development.
    P1 data • PK/PD data • Journal
    |
    IL2 (Interleukin 2) • MALT1 (MALT1 Paracaspase)
    |
    Noxafil (posaconazole) • SGR-1505
    2ms
    Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) (clinicaltrials.gov)
    P3, N=664, Not yet recruiting, University of Minnesota
    New P3 trial
    |
    itraconazole • Noxafil (posaconazole)
    2ms
    Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations (clinicaltrials.gov)
    P=N/A, N=15, Completed, Fondazione IRCCS Policlinico San Matteo di Pavia
    New trial
    |
    Venclexta (venetoclax) • Noxafil (posaconazole)
    2ms
    MOMENTUM: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (clinicaltrials.gov)
    P1/2, N=84, Not yet recruiting, AstraZeneca | Trial completion date: Jun 2029 --> Feb 2029 | Trial primary completion date: Jun 2029 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    Noxafil (posaconazole)
    3ms
    Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies. (PubMed, J Antimicrob Chemother)
    Although co-administration of posaconazole with ruxolitinib resulted in a statistically significant increase in ruxolitinib systemic exposure, the magnitude of this interaction was clinically moderate. Although ruxolitinib dose adjustment may not be routinely required when used concomitantly with posaconazole, close monitoring for ruxolitinib-related adverse effects is recommended under this combination therapy setting.
    PK/PD data • Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    Jakafi (ruxolitinib) • Noxafil (posaconazole)
    4ms
    Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    Noxafil (posaconazole)
    5ms
    MOMENTUM: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (clinicaltrials.gov)
    P1/2, N=84, Not yet recruiting, AstraZeneca
    New P1/2 trial
    |
    Noxafil (posaconazole)
    5ms
    Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) (clinicaltrials.gov)
    P2, N=40, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Noxafil (posaconazole)